Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,038,990.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $530.42, for a total transaction of $5,038,990.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $172,091,056.06. The trade was a 2.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $525.82 on Friday. The company’s fifty day moving average price is $544.65 and its 200 day moving average price is $532.54. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The firm has a market capitalization of $22.32 billion, a P/E ratio of 19.41, a P/E/G ratio of 1.75 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $6.63 EPS. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 26.65 EPS for the current year.

Analyst Ratings Changes

Several research analysts have commented on UTHR shares. Raymond James Financial initiated coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target on the stock. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Bank of America cut their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Finally, Royal Bank Of Canada upped their price target on shares of United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $648.33.

Hedge Funds Weigh In On United Therapeutics

Large investors have recently bought and sold shares of the company. Avoro Capital Advisors LLC lifted its stake in shares of United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after acquiring an additional 383,838 shares during the period. Wellington Management Group LLP increased its stake in shares of United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares during the period. AQR Capital Management LLC raised its holdings in United Therapeutics by 29.9% during the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after purchasing an additional 295,221 shares in the last quarter. Janus Henderson Group PLC raised its holdings in United Therapeutics by 8.9% during the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after purchasing an additional 70,829 shares in the last quarter. Finally, Norges Bank acquired a new stake in United Therapeutics in the fourth quarter valued at about $293,418,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.